Correction: Case Report on Complete Response and Extended Survival with Alectinib in a NSCLC Patient Exhibiting a Rare WDR43::ALK Structural Deletion

Overview

This correction addresses errors in the figures of a previously published case report on alectinib's efficacy in a patient with a rare WDR43::ALK structural deletion. The corrected figures clarify mislabeling and duplication issues present in the original publication.

Background

ALK rearrangements are significant in non-small cell lung cancer (NSCLC), influencing treatment options and outcomes. Alectinib is a targeted therapy used for treating ALK-positive NSCLC. Accurate reporting of case studies is crucial for advancing understanding and clinical application of these therapies.

Data Highlights

No numerical or trial data is presented in the correction notice.

Key Findings

• Correction of Figure 1, which was mislabeled as ML4::ALK instead of EML4::ALK.
• Correction of Figure 3, which was mistakenly replaced with a duplicate of Figure 1.
• The original article has been updated to reflect these corrections.
• ALK-positive NSCLC cases can exhibit rare structural deletions.
• Accurate figure representation is essential for the integrity of clinical case reports.

Clinical Implications

Clinicians should ensure that case reports are accurately represented to avoid misinterpretation of data.

Conclusion

The corrections made to the figures in this case report enhance the clarity of the findings related to alectinib's efficacy in a rare ALK structural deletion case.

Related Resources & Content

1. Epler L, Velasquez G, Mambetsariev I, et al., Front. Oncol., 2026 -- Correction on Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion
2. Frontiers in Oncology — Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma
3. Frontiers in Oncology — Durable response to ALK inhibition in low-allele-frequency SPTBN1–ALK–rearranged gastric cancer followed by lineage plasticity–mediated resistance: a case report
4. Frontiers in Oncology — Postoperative Treatment Decisions Informed by Minimal Residual Disease in a Patient with ALK-Rearranged Adenocarcinoma: A Case Study
5. Frontiers in Oncology — Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report
6. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0
7. Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study - ScienceDirect
8. Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions – a real-world retrospective analysis | npj Precision Oncology